In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model

Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission...

Descripción completa

Detalles Bibliográficos
Autores principales: Csikos, Csaba, Vágner, Adrienn, Nagy, Gábor, Kálmán-Szabó, Ibolya, Szabó, Judit P., Ngo, Minh Toan, Szoboszlai, Zoltán, Szikra, Dezső, Krasznai, Zoárd Tibor, Trencsényi, György, Garai, Ildikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/
https://www.ncbi.nlm.nih.gov/pubmed/36673046
http://dx.doi.org/10.3390/diagnostics13020236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/
https://www.ncbi.nlm.nih.gov/pubmed/36673046
http://dx.doi.org/10.3390/diagnostics13020236

Ejemplares similares